SNPs to Risk of Metastasis (SToRM)

Contact: David Cox, M.S., Ph.D.

Number of Enrolled Cancer Patients/Survivors: 1,000
Years of Diagnoses of Enrolled Cancer Patients/Survivors: N/A
Approximate Years of Follow-up: N/A
Cancer Sites Represented: Metastatic Breast Cancers
Biological Specimens Collected: Blood/Blood Fraction
Germline DNA
Treatment Outcome Measures: Physician/Medical Record Reported
  • Symptom Assessment
  • Acute Medical Event
  • Late Medical Event
  • Cancer Recurrence
  • Death
Patient-Reported
  • Quality of Life
  • Other
  • Cancer Recurrence
  • Death
  • Other: Birth Registry Variables
  • Other: Drug Prescriptions
Co-morbidities at Study Entry: None
Lifestyle Factors: Smoking
Alcohol Use
Physical Activity
Body Mass Index
Other
Treatment Data: Surgery
Radiation
Chemotherapy
Hormonal Therapy
Treatment Data Assessed By: Chart Abstraction
Other
Is the study open to collaboration? Yes
Additional Information: We are currently recruiting patients into a French nationwide clinical study of metastatic breast cancer. Cases are included within 12 months of diagnosis of the metastasis, with medical history recorded via questionnaires filled out by the oncologist. 130 patients have been included since May 2013, and we aim to include 1000 patients by May 2015. The main aim of the study is to test genetic susceptibility to metastatic progression, with secondary aims to investigate survival after metastasis. Buffy coats, plasma, and erythrocytes will be available for all subjects. We will also work to identify patients that have archived primary tumor blocks and metastatic biopsies available for subsequent analyses if possible. Our study is registered with clinicaltrials.govExternal Web Site Policy (identifier NCT01460186).

Return to Top